Table 2.
Main Characteristics of the Randomized Clinical Trials Selected for the Meta-Analysis
| Trial | Phase | Histology | No. of Intervention/Control | Arms of Treatment | Primary Outcome | TRAEs Reported |
|---|---|---|---|---|---|---|
| KEYNOTE 0216,7 | II | Nonsquamous | 60/63 | Pembrolizumab + carboplatin + pemetrexed vs. carboplatin + pemetrexed |
ORR | Yes |
| KEYNOTE 18910,11 | III | Nonsquamous | 410/206 | Pembrolizumab + cisplatin or carboplatin + pemetrexed vs. cisplatin or carboplatin + pemetrexed |
PFS, OS | No |
| KEYNOTE 4078,9 | III | Squamous | 278/281 | Pembrolizumab + carboplatin + nab-paclitaxel or paclitaxel vs. carboplatin + nab-paclitaxel or paclitaxel |
PFS, OS | Yes |
| ORIENT-1112 | III | Nonsquamous | 266/131 | Sintilimab + pemetrexed + cisplatin or carboplatin vs. pemetrexed + cisplatin or carboplatin |
PFS, OS | No |
| IMpower13015 | III | Nonsquamous | 483/240 | Atezolizumab + carboplatin + nab-paclitaxel vs. carboplatin + nab-paclitaxel |
PFS, OS | Yes |
| IMpower13113 | III | Squamous | 343/340 | Atezolizumab + carboplatin + nab-paclitaxel vs. carboplatin + nab-paclitaxel |
PFS, OS | Yes |
| IMpower13216 | III | Nonsquamous | 292/286 | Atezolizumab + cisplatin or carboplatin + pemetrexed vs. cisplatin or carboplatin + pemetrexed |
PFS, OS | Yes |
| IMpower15014 | III | Nonsquamous | 400/400 | Atezolizumab + bevacizumab + carboplatin + paclitaxel vs. bevacizumab + carboplatin + paclitaxel |
PFS, OS | Yes |
ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TRAE, treatment-related adverse event.